A prospective multicentre study aims to identify biomarker combinations that can accurately diagnose acute mesenteric ischaemia (AMI) and distinguish between reversible and irreversible bowel ischaemia. Serum biomarkers including I-FABP, Alpha-GST, IL-6, PCT, IMA, D-lactate, D-dimer, SCUBE-1, and LBP will be measured in adult patients with suspected AMI. The study will develop a practical score for diagnosing AMI and guiding treatment decisions based on the identified biomarker combinations, potentially offering an improved method for early diagnosis and treatment planning in patients with AMI.
Journal Article by Tamme K, Acosta S (…) Reintam Blaser A et 15 al. in BMC Surg
© 2024. The Author(s).